Elena Nikulina

OCU400 available through commercial expanded access in the Bahamas, Ocugen outlines

OCU400 available through commercial expanded access in the Bahamas, Ocugen outlines
Ocugen launches OCU400 in Bahamas

Ocugen is facilitating access to OCU400 for patients with retinitis pigmentosa in the Bahamas through an Expanded Access Program that allows commercial pricing.

The initiative is supported by the LARTA Board and the Ministry of Health and Wellness in the Bahamas, aiming to make gene therapy available to patients worldwide.

Ocugen recently named Beth Scott as Head of Clinical Development to strengthen its leadership in advanced retinal therapy trials, according to a company announcement. The firm also hosted Pennsylvania lawmakers at its facility to discuss its biotech pipeline and ongoing innovation within the state, as noted in a previous engagement. These steps demonstrate Ocugen’s ongoing efforts to expand access and advance its gene therapy programs.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.